Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGO in Refractory AML and MDS
NCT03839446Phase 2Completed
- Start
- Feb 2019
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Started Feb 2019; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03839446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839446.